Cost variation analysis of anti-epileptic drugs available in the Indian market
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20251841Keywords:
Anti-epileptic drugs, Cost variation, Indian marketAbstract
Background: Epilepsy is a chronic, noncommunicable disease of the brain affecting 50 million people worldwide. Out-of-pocket expenditure (OOPE) remains a major burden for Indian households, leading to poor adherence in epilepsy treatment. Many patients discontinue therapy due to high costs, worsening disease outcomes. This study aimed to analyse price variations among different brands of anti-epileptic drugs (AEDs) available in India.
Methods: The prices in Indian rupees for all AEDs of same strength manufactured by different pharmaceutical companies in the Indian market were obtained from Current Index of Medical Specialities (CIMS) 3rd update 2024, Indian drug review (IDR) 2024 issue and National Pharmaceutical Pricing Authority (NPPA)-Pharma Sahi Daam. The cost ratio was calculated by dividing the price of the costliest brand by the price of the least costly brand. The percentage cost variation was determined by subtracting the minimum cost from the maximum cost, dividing it by the minimum cost and multiplying by 100.
Results: Analysis of 1708 brands of 23 single AEDs and 112 brands of fixed dose combinations (FDCs) in India revealed wide cost variations. Clonazepam showed highest percentage cost variation and cost ratio among single drugs, while Oxcarbazepine and Sodium valproate had the lowest percentage cost variation and cost ratio, respectively.
Conclusions: The study highlights significant cost disparities among different brands of AEDs, affecting patients’ OOPEs. Clinicians should therefore consider these price variations to prescribe cost-effective treatments, improving patient compliance and disease outcomes. The findings also emphasize need for regulatory measures to promote equitable and affordable drug pricing.
Metrics
References
WHO. Fact sheet: Epilepsy. Available at: https://www.who.int/news-room/fact. Accessed on 22 January 2025.
Garg, Divyani. Specific Considerations for Epilepsy in India. Current Med Issues. 2020;18(2):105-10. DOI: https://doi.org/10.4103/cmi.cmi_6_20
Thurman DJ, Logroscino G, Beghi E. The burden of premature mortality of epilepsy in high-income countries: A systematic review from the Mortality Task Force of the International League Against Epilepsy. Epilepsia. 2017;58(1):17–26. DOI: https://doi.org/10.1111/epi.13604
Sinha A, Bhaumik DK. Treatment expenditure pattern of epileptic patients: a study from a tertiary care hospital, Kolkata, India. Neurol Res Int. 2014;2014:869572. DOI: https://doi.org/10.1155/2014/869572
UK NC. The epilepsies: The diagnosis and management of the epilepsies in adults and children in primary and secondary care. 2012.
Radhakrishnan K. Challenges in the management of epilepsy in resource-poor countries. Nature Rev Neurol. 2009;5(6):323-30. DOI: https://doi.org/10.1038/nrneurol.2009.53
Eaddy MT, Cook CL, O’Day K, Burch SP, Cantrell CR. How patient cost-sharing trends affect adherence and outcomes: a literature review. Pharm Therap. 2012;37(1):45.
Sarangi SC, Kaur N, Tripathi M. Need for pharmacoeconomic consideration of antiepileptic drugs monotherapy treatment in persons with epilepsy. Saudi Pharma J. 2020;28(10):1228-37. DOI: https://doi.org/10.1016/j.jsps.2020.08.013
Ambade M, Sarwal R, Mor N, Kim R, Subramanian SV. Components of Out-of-Pocket Expenditure and Their Relative Contribution to Economic Burden of Diseases in India. JAMA Netw Open. 2022;5(5):2210040. DOI: https://doi.org/10.1001/jamanetworkopen.2022.10040
Ray A, Najmi A, Khandelwal G, Sadasivam B. A cost variation analysis of drugs available in the Indian market for the management of thromboembolic disorders. Cureus. 2020;12(5):8712.
Pharma Industry in India. Pharma Sector Overview, Market Size, Analysis. India Brand Equity Foundation (IBEF). Available at https://www.ibef.org/industry. Accessed on 21 January 2025.
Arya P, Kumar R, Chandra A, Mohan L. Study of price variations of anti-epileptic drugs available in different brands in Indian pharmaceutical market. International J Res Med Sci. 2018;6(12):4102. DOI: https://doi.org/10.18203/2320-6012.ijrms20184914
Kumar H, Kesari US, Kumar R. Study of the cost variation analysis of anti-epileptic drugs available in different brands in Indian pharmaceutical market. International J Bas Clin Pharmacol. 2021;10(5):523-7. DOI: https://doi.org/10.18203/2319-2003.ijbcp20211647
Sai NP, Vedavathi H. Cost analysis study of price variation among the various brands of antiepileptics available in India. Int J Basic Clin Pharmacol. 2017;6:422-6. DOI: https://doi.org/10.18203/2319-2003.ijbcp20170342
Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: a systematic review. PLoS Med. 2007;4(9):283. DOI: https://doi.org/10.1371/journal.pmed.0040283
Baru M, Acharya A, Acharya S, Kumar AS, Nagraj K. Inequities in access to health services in india: caste, class and region. Econ Polit Wkly. 2010;45:49-58.
Rataboli PV, Garg A. Confusing brand names: Nightmare of medical profession. J Postgrad Med. 2005;51:13-6.
Chaturvedi A, Dubey AK, Naveen A, Sravani MR. Perceived utility of jam Aushadhi outlets and awareness of generic medicines at the Andaman and Nicobar Islands: a cross-sectional study. Cureus. 2024;16(4):57630. DOI: https://doi.org/10.7759/cureus.57630
PMBJP Scheme. Available at https://janaushadhi.gov.in/pmbjb-scheme. Accessed on 23 January 2025.
Ray A, Najmi A, Khandelwal G, Sadasivam B. A Cost Variation Analysis of Drugs Available in the Indian Market for the Management of Thromboembolic Disorders. Cureus. 2020;5;12(5):7964. DOI: https://doi.org/10.7759/cureus.7964
Downloads
Published
How to Cite
Issue
Section
